LEARNING ABOUT FANCONI ANEMIA
|
|
- Easter Walker
- 5 years ago
- Views:
Transcription
1 opyr LEARNING ABOUT FANCONI ANEMIA *Jacqueline Rosenberg *Justin Mark Artwork By: Jacqueline Rosenberg 00 Posters. Ccted. F1000
2 OVERVIEW Fanconi Anemia (FA) is a rare disease of the blood that leads to failure of the bone marrow as well as other organs and tissues This genetic disorder may be prevalent in all races and ethnicities. However, it is most common in Ashkenazi Jews and Native South Africans 1 Each year, 1 out of 360,000 people are born with the disorder: 1 out of 30,000 are Jews 1 out of 22,000 are South Africans opyr 1 out of 300 people are carriers for the disease: 1 out of 90 Jews 1 out of 77 South Africans The disease is caused by mutations of various genes: In 99% of cases, an autosomal recessive pattern is shown The remaining 1% displays an X-linked recessive inheritance 2 Although the child is born with the disease, symptoms may not present until ages 2 to 15 and a diagnosis is typically made at this time 3 00 Posters. Ccted. F1000
3 CAUSES Genetic analysis indicates a mutation in 1 of 15 genes as the etiology for FA An inheritance of any mutation in the BRCA1, RAD51, FANCA, B, C, E, F, G, I, J, L, M or N gene may result in the disease 2 Mechanism of action 4 : Genes FANCD2 and FANCI become ubiquitylated, which disrupts various DNA repair mechanisms and destabilizes the genome This eventually causes malfunction of the bone marrow as well as increased susceptibility to cancer Various theories indicate 3 : -Hematopoietic stem cells may become damaged -Mutated cells have increased sensitivity to free radicals -The cell cycle becomes deregulated opyr 00 Posters. Ccted. F1000
4 HISTORY In 1927, Guido Fanconi was the first to discover the disease in three brothers These brothers presented with pancytopenia, aplastic anemia, and physical abnormalities 5 opyr 00 Posters. Ccted. F1000
5 SYMPTOMS The major symptoms of FA are 6 : Aplastic Anemia Bone Marrow Defects opyr Patients with FA show a high incidence of Acute Myeloid Leukemia (AML) 00 Posters. Ccted. F1000
6 SYMPTOMS More physical symptoms include 7 : Thumb and arm anomalies Abnormalities of the hips, spine or ribs Kidney problems. Skin discoloration opyr Small head or eyes Mental retardation or learning disabilities Low birth weight Gastrointestinal difficulties Small reproductive organs in males Defects in tissues separating chambers of the heart 00 Posters. Ccted. F1000
7 SUBTYPES OF FA The subtypes of FA refer to which gene the mutation is present Type C is the form that is most common in Ashkenazi Jews opyr 00 Posters. Ccted. F1000
8 DIAGNOSTIC PROCEDURES FA is most reliably diagnosed by using genetic testing: Chromosome Breakage Test 8 Blood cells are extracted and the DNA is tested using crosslinking chemicals, such as Diepoxybutane and Mitomycin C Normal DNA are able to repair these newly formed linkages opyr FA- induced damaged DNA more likely to show chromosome breakages This test may be performed prenatally by testing either the amniotic fluid or the chorionic villi 00 Posters. Ccted. F1000
9 OTHER DIAGNOSTIC PROCEDURES Flow Cytometry 9 Upon treatment with nitrogen mustard, damaged DNA shows a characteristic pattern in the cell cycle compared to normal DNA Studies show that DNA damaged from FA are more likely to be arrested in the G2/M phase opyr 00 Posters. Ccted. F1000
10 PROGNOSIS 10 The median survival age of FA patients is 20 years old, with an increase to 30 years within the last 10 years Bone marrow failure serves as the major cause of fatalities from the disease opyr Myelodysplastic disorders, Leukemia, Cancers of the head, neck, and esophagus and solid tumors in the liver frequently develop Undergoing a successful bone marrow transplant has shown an increase in survival rate 00 Posters. Ccted. F1000
11 MEDICINAL TREATMENT OF FA- ASSOCIATED APLASTIC ANEMIA There are four main categories of drugs used to counteract aplastic anemia 11 : Androgenic agents stimulate the production of erythropoietin in the kidneys with damaged bone marrow or erythropoiesis due to the lack of red blood cells Anadrol- 50 (Oxymetholone) is a testosterone derivative that increases the above processes opyr Antifibrinolytic agents decrease bleeding by protecting blood clots Amicar (aminocaproic acid) inhibits the conversion of fibrinogen to fibrin, a protein that degrades blood clots Hematopoietic growth factors help stimulate the proliferation, differentiation and activation of various blood cells G-CSF, Neupogen (Filgrastim ) helps produce functional neutrophils Epogen, Procrit (Epoetin alfa) helps in the differentiation of erythroid progenitor cells Glucocorticoids help counteract the growth effects from androgens. They may also help reduce bleeding Prednisone is used for anti-inflammatory purposes and suppression of the immune system 00 Posters. Ccted. F1000
12 TREATMENT OF OTHER FA-ASSOCIATED ABNORMALITIES A bone marrow transplant or other types of hematopoietic stem cell treatment is necessary and is the only current cure of the aplastic anemia The appropriate surgical care can be used to address the multitude of physical symptoms opyr i.e. Cardiovascular, Orthopedic, Plastic, GI or Oncological Surgeries 00 Posters. Ccted. F1000
13 CLINICAL TRIALS Gene Therapy Trials in Mice 12 Scientists have used the Lentivirus for the transduction of normal FANCA and FANCC genes into mice These genes were able to be incorporated into the genome of the mice and were properly expressed Hematopoietic progenitors were adequately repaired to stimulate precursor cell proliferation opyr Bone marrow damage was corrected The mice DNA was protected against the cross-linking chemicals Thus, these trials have shown a great deal of promise with FA gene viral transduction in humans 00 Posters. Ccted. F1000
14 CLINICAL TRIALS Bone marrow tissue, hematopoietic progenitor cells, and DNA samples are constantly being obtained and analyzed in order to gain new knowledge on the disease opyr PCR, Western Blotting, Gel Electrophoresis, Chromatography, and Microarray analysis techniques used 00 Posters. Ccted. F1000
15 SCIENTISTS/ CLINICIANS Swiss Pediatrician Dr. Guido Fanconi was the first to describe the disease Presently, a few of the major researchers on the disease include: Dr. Markus Grompe, M.D.- Professor at Oregon Health & Science University opyr Dr. Agata Smogorzewska, M.D., Ph.D, Dr. Arleen Auerbach, Ph.D, Dr. Elizabeth Garner, Postdoctoral Associate- The Rockefeller University Dr. Andre Rogatko, Ph.D- Professor at Emery University and Researcher at Samuel Oschin Comprehensive Cancer Institute and Cedars Sinai Medical Center 00 Posters. Ccted. F1000
16 RODENT MODELS Scientists have reproduced various FA gene mutations in mice to experimentally determine any functional differences FANCA and FANCC mutations studies in mice have concluded no known differences These genes are part of the FA pathway that act together in response to DNA damage, proliferate hematopoietic precursors and ensure the survival of germ cells 13 opyr This is merely one rodent model of FA, as many studies have indicated the mechanism of action of the disease 00 Posters. Ccted. F1000
17 AGENCIES, SOCIETIES, SUPPORT, CONFERENCES opyr FANCONI Phone: National Heart, Lung, Blood Institute 00 Posters. Ccted. F1000
18 FAMOUS PATIENTS Since the disease is quite rare, there have yet to be any famous cases of FA. opyr 00 Posters. Ccted. F1000
19 CONCLUSIONS Fanconi Anemia is a rare autosomal recessive disease that occurs because of damage to one or more genes of the FA pathway. This pathway is responsible for DNA repair and the proliferation of hematopoietic progenitor cells. Any mutation in an FA gene will lead to aplastic anemia and failure of the bone marrow, as well as physical abnormalities and a high likely hood for a form of cancer. Research has shown promise in the survival rate of the disease both because of more reliable bone marrow transplants and advanced knowledge of the pathway in both rodents and humans. opyr 00 Posters. Ccted. F1000
20 REFERENCES 1 "Fanconi Anemia in Ashkenazi Jews and Afrikaners." National Heart, Lung and Blood Institute. Web. 06 June < 2 Alter, MD, MPH, FAAP, Blanche P. "Fanconi Anemia Etiology." Medscape Reference. Ed. Jeffery M. Lipton, MD, PhD and Max J. Coppes, MD, PhD, MBA Web. 6 June < overview#aw2aab6b2b2aa>. 3 "Fanconi Anemia Diagnosis, Genetic Testing." National Heart, Lung and Blood Institute. Web. 06 June < 4 Garner, E., and A. Smogorzewska. "Ubiquitylation and the Fanconi Anemia Pathway." Federation of the Biochemistry Society Letters (2011). PubMed. Elsevier B.V, 19 May Web. 06 June < 5 Alter, MD, MPH, FAAP, Blanche P. "Fanconi Anemia Background." Medscape Reference. Ed. Jeffery M. Lipton, MD, PhD and Max J. Coppes, MD, PhD, MBA Web. 6 June < opyr 6 "Fanconi Anemia Symptoms." National Heart, Lung and Blood Institute. Web. 06 June < 7 "FA Fact Sheet." Home Fanconi Anemia Research Fund. Fanconi Anemia Research Fund, Inc. Web. 06 June < 8 Auerbach, AD, A. Rogatko, and TM Schroeder-Kurth. "International Fanconi Anemia Registry: Relation of Clinical Symptoms to Diepoxybutane Sensitivity." Blood 73.2 (1989): PubMed. Web. 11 June < 9 Berger, R., M. Le Coniat, and MC Gendron. "Fanconi Anemia. Chromosome Breakage and Cell Cycle Studies." Cancer Genetics and Cytogenetics 69.1 (1993): PubMed. 20 Jan Web. 11 June < 10 Alter, MD, MPH, FAAP, Blanche P. "Fanconi Anemia Prognosis." Medscape Reference. Ed. Jeffery M. Lipton, MD, PhD and Max J. Coppes, MD, PhD, MBA Web. 6 June < overview#aw2aab6b2b4aa> 11 Alter, MD, MPH, FAAP, Blanche P. "Fanconi Anemia Medication." Medscape Reference. Ed. Jeffery M. Lipton, MD, PhD and Max J. Coppes, MD, PhD, MBA Web. 6 June < medication#5> 00 Posters. Ccted. F1000
21 REFERENCES 12 Galimi, F., M. Noll, Y. Kanazawa, T. Lax, C. Chen, M. Grompe, and IM Verma. "Gene Therapy of Fanconi Anemia: Preclinical Efficacy Using Lentiviral Vectors." Blood (2002): PubMed. 21 June Web. 11 June < 13 Noll, M., KP Battaile, R. Bateman, TP Lax, K. Rathbun, C. Reifsteck, G. Bagby, M. Finegold, S. Olsen, and M. Grompe. "Fanconi Anemia Group A and C Double-mutant Mice: Functional Evidence for a Multi-protein Fanconi Anemia Complex." Experimental Hematology 30.7 (2002): PubMed. 16 Apr Web. 11 June < A special thanks to Dr. Rosalind Silverman, Dr. Lorelei Silverman, and the Models of Human Disease Conference at the University of Toronto opyr 00 Posters. Ccted. F1000
Constitutional Aplastic Anemias. Uma Kundu, M.D. July 17, 2006
Constitutional Aplastic Anemias Uma Kundu, M.D. July 17, 2006 Overview Erythroid lineage only (pure red cell aplasia) Two cell lines (bicytopenia) All hematopoietic cells (aplastic anemia) Aplastic anemias
More informationCancer Epidemiology. Blanche P Alter, MD, MPH, FAAP Clinical Genetics Branch Division of Cancer Epidemiology and Genetics Bethesda, MD
Cancer Epidemiology Blanche P Alter, MD, MPH, FAAP Clinical Genetics Branch Division of Cancer Epidemiology and Genetics Bethesda, MD Fanconi Anemia Adults, February 2011 Outline Epidemiology FA Literature
More information7/13/2017. PreventionGenetics. How are genes associated with bone marrow failure?
Personalized Medicine: tic Testing and the Implications for Future Therapies Preventiontics Michael Chicka, PhD, Molecular ticist, Preventiontics Founded in 2004 in Marshfield Wisconsin by Dr. Jim Weber
More informationChapter 15: Non-Head and Neck Solid Tumors in Patients with Fanconi Anemia
Chapter 15: Non-Head and Neck Solid Tumors in Patients with Fanconi Anemia Introduction Cancer is a major concern in FA patients. This chapter will describe the most common types of non-head and neck solid
More informationGENETIC TESTING FOR FANCONI ANEMIA
GENETIC TESTING FOR FANCONI ANEMIA Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices
More informationFanconi Anemia 101. Blanche P Alter, MD, MPH, FAAP Clinical Genetics Branch Division of Cancer Epidemiology and Genetics Bethesda, MD
Fanconi Anemia 101 Blanche P Alter, MD, MPH, FAAP Clinical Genetics Branch Division of Cancer Epidemiology and Genetics Bethesda, MD FA Camp, August 10, 2012 When You Hear., Think., Or. Horses Zebras Unicorns
More informationINHERITED PANCYTOPENIA SYNDROMES Fanconi anemia Shwachman-Diamond syndrome Dyskeratosis congenita Congenital amegakaryocytic thrombocytopenia
The Pancytopenias The Inherited Pancytopenias Pancytopenia refers to a reduction below normal values of all 3 peripheral blood component: leukocytes, platelets, and erythrocytes. Pancytopenia requires
More informationPresents... Corporate Sponsorship Package
Presents... Corporate Sponsorship Package Presents... What: Annual fund raising event of the Kendall and Taylor Atkinson (KATA) Foundation. This year s event is a western-themed gala with silent and live
More informationCancer Epidemiology in Fanconi Anemia
Cancer Epidemiology in Fanconi Anemia FA Camp 2010 Blanche P Alter, MD, MPH, FAAP Clinical Genetics Branch Division of Cancer Epidemiology and Genetics Bethesda, MD Resources Source N Retrospective: Literature
More informationChapter 2. Diagnostic Evaluation of FA. Definition of Fanconi Anemia. The Importance of Early Diagnosis. Blanche P. Alter, MD, MPH, FAAP
Chapter 2 Diagnostic Evaluation of FA Blanche P. Alter, MD, MPH, FAAP Definition of Fanconi Anemia Fanconi anemia is an autosomal recessive disorder associated with a very high frequency of bone marrow
More informationMYELODYSPLASTIC SYNDROMES
MYELODYSPLASTIC SYNDROMES Babak Tamizi Far MD. Assistant professor of internal medicine Al-zahra university hospital, Isfahan university of medical sciences Key Features ESSENTIALS OF DIAGNOSIS Cytopenias
More informationPrecursor T acute lymphoblastic leukemia from myelodysplastic syndrome in Fanconi anemia
J Hematopathol (2013) 6:161 165 DOI 10.1007/s12308-012-0168-2 CASE REPORT Precursor T acute lymphoblastic leukemia from myelodysplastic syndrome in Fanconi anemia Julie C. Dueber & Claudio Mosse & Catherine
More informationHematopoietic Cell Transplantation in Bone Marrow Failure Syndromes
Hematopoietic Cell Transplantation in Bone Marrow Failure Syndromes The The 44 th th WBMT WBMT SYMPOSIUM 2017 2017 Riyadh, Saudi Saudi Arabia Arabia Mouhab Mouhab Ayas, Ayas, MD MD Department of Pediatric
More informationThe function of the bone marrow. Living with Aplastic Anemia. A Case Study - I. Hypocellular bone marrow failure 5/14/2018
The function of the bone marrow Larry D. Cripe, MD Indiana University Simon Cancer Center Bone Marrow Stem Cells Mature into Blood Cells Mature Blood Cells and Health Type Function Term Red Cells Carry
More informationOriginal Policy Date
MP 2.04.76 Genetic Counseling Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Created Local Policy/ 12:2013 Return to Medical Policy Index Disclaimer
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name and description (please provide any alternative names you wish listed) (A)-Testing
More informationOutline. What is aplastic anemia? 9/19/2012. Aplastic Anemia Current Thinking on the Disease, Diagnosis, and Non-Transplant Treatment Options
Aplastic Anemia Current Thinking on the Disease, Diagnosis, and Non-Transplant Treatment Options Carlos M. de Castro, MD Duke University Medical Center Outline What is Aplastic Anemia? What other diseases
More informationCONTRACTING ORGANIZATION: Oregon Health & Science University Portland OR 97239
AWARD NUMBER: W81XWH-16-1-0300 TITLE: Metformin Therapy for Fanconis Anemia PRINCIPAL INVESTIGATOR: Markus Grompe CONTRACTING ORGANIZATION: Oregon Health & Science University Portland OR 97239 REPORT DATE:
More informationSeptember 20, Submitted electronically to: Cc: To Whom It May Concern:
History Study (NOT-HL-12-147), p. 1 September 20, 2012 Re: Request for Information (RFI): Building a National Resource to Study Myelodysplastic Syndromes (MDS) The MDS Cohort Natural History Study (NOT-HL-12-147).
More informationHematopoietic Growth Factors Colony Stimulating Factors. Erythropoietin (Epoetin alfa). Granulocyte-macrophage colonystimulating factor (G-CSF).
Hematopoietic Growth Factors Colony Stimulating Factors. Erythropoietin (Epoetin alfa). Granulocyte colony-stimulating factor(g-csf). Granulocyte-macrophage colonystimulating factor (G-CSF). Interleukin-11
More informationStem Cell Transplantation for Severe Aplastic Anemia
Number of Transplants 10/24/2011 Stem Cell Transplantation for Severe Aplastic Anemia Claudio Anasetti, MD Professor of Oncology and Medicine Chair, Blood and Marrow Transplant Dpt Moffitt Cancer Center
More informationGranix. Granix (tbo-filgrastim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.16 Subject: Granix 1 of 7 Last Review Date: December 2, 2016 Granix Description Granix (tbo-filgrastim)
More informationConstitutional Hypoplastic Anemia
Kamla-Raj 2002 Int J Hum Genet, 2 (3): 179-184 (2002) Constitutional Hypoplastic Anemia Neelam Varma KEY WORDS Constitutional anemia; congenital; inherited; screening ABSTRACT A large number of patients
More informationGranix. Granix (tbo-filgrastim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.16 Subject: Granix 1 of 6 Last Review Date: September 15, 2017 Granix Description Granix (tbo-filgrastim)
More informationTreatment of low risk MDS
Treatment of low risk MDS Matteo G Della Porta Cancer Center IRCCS Humanitas Research Hospital & Humanitas University Rozzano Milano, Italy matteo.della_porta@hunimed.eu International Prognostic Scoring
More informationGranix. Granix (tbo-filgrastim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.16 Section: Prescription Drugs Effective Date: April 1, 2014 Subject: Granix 1 of 7 Last Review Date:
More informationGranix. Granix (tbo-filgrastim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.16 Subject: Granix 1 of 7 Last Review Date: September 18, 2015 Granix Description Granix (tbo-filgrastim)
More informationLegends for Supplemental Figures.
1 Legends for Supplemental Figures. Supplemental Figure 1. Proteasome Inhibition does not abrogate the expression of FA core complex proteins or formation of the FA core complex. (Full-length blots are
More informationTOUR REPORT. Report on participation of the ICMR International Fellow (ICMR IF) in Training / Research abroad
TOUR REPORT Report on participation of the ICMR International Fellow (ICMR IF) in Training / Research abroad 1. Name and Designation of ICMR IF : Dr. A. Venkateshwari, Assistant Professor 2. Address: Dr.
More informationWelcome to the fifteenth issue of the FA Courier, outlining
Welcome to the fifteenth issue of the FA Courier, outlining current requests for materials and clinical trials connected to Fanconi anemia (FA) research. We publish the FA Courier: To encourage families
More informationLet s Look at Our Blood
Let s Look at Our Blood Casey O Connell, MD Associate Professor of Clinical Medicine Jane Anne Nohl Division of Hematology Keck School of Medicine of USC 10,000,000,000 WBCs/day Bone Marrow: The Blood
More informationIntroduction to Evaluating Hereditary Risk. Mollie Hutton, MS, CGC Certified Genetic Counselor Roswell Park Comprehensive Cancer Center
Introduction to Evaluating Hereditary Risk Mollie Hutton, MS, CGC Certified Genetic Counselor Roswell Park Comprehensive Cancer Center Objectives Describe genetic counseling and risk assessment Understand
More informationYear 2002 Paper two: Questions supplied by Jo 1
Year 2002 Paper two: Questions supplied by Jo 1 Question 70 A 25 year old previously well male student presents with recent exertional dyspnoea, epistaxis and bruising. There is no history of medication,
More informationWhat is New in Genetic Testing. Steven D. Shapiro MS, DMD, MD
What is New in Genetic Testing Steven D. Shapiro MS, DMD, MD 18th Annual Primary Care Symposium Financial and Commercial Disclosure I have a no financial or commercial interest in my presentation. 2 Genetic
More informationLeukine. Leukine (sargramostim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Leukine Page: 1 of 6 Last Review Date: November 30, 2018 Leukine Description Leukine (sargramostim)
More informationFanconi Anemia 101. Blanche P Alter, MD, MPH, FAAP Clinical Genetics Branch Division of Cancer Epidemiology and Genetics Bethesda, MD
Fanconi Anemia 101 Blanche P Alter, MD, MPH, FAAP Clinical Genetics Branch Division of Cancer Epidemiology and Genetics Bethesda, MD FA Camp, June 27, 2014 When You Hear., Think., Or. Horses Zebras Unicorns
More informationAgro/Ansc/Bio/Gene/Hort 305 Fall, 2017 MEDICAL GENETICS AND CANCER Chpt 24, Genetics by Brooker (lecture outline) #17
Agro/Ansc/Bio/Gene/Hort 305 Fall, 2017 MEDICAL GENETICS AND CANCER Chpt 24, Genetics by Brooker (lecture outline) #17 INTRODUCTION - Our genes underlie every aspect of human health, both in function and
More informationAcute Myeloid Leukemia: A Patient s Perspective
Acute Myeloid Leukemia: A Patient s Perspective Patrick A Hagen, MD, MPH Cardinal Bernardin Cancer Center Loyola University Medical Center Maywood, IL Overview 1. What is AML? 2. Who gets AML? Epidemiology
More informationDone By : WESSEN ADNAN BUTHAINAH AL-MASAEED
Done By : WESSEN ADNAN BUTHAINAH AL-MASAEED Acute Myeloid Leukemia Firstly we ll start with this introduction then enter the title of the lecture, so be ready and let s begin by the name of Allah : We
More informationAldehydes: What Are They and Why Should They be Avoided
Aldehydes: What Are They and Why Should They be Avoided Alan D Andrea, M.D. Fuller-American Cancer Society Professor Dana-Farber Cancer Institute Harvard Medical School Boston, MA, U.S.A. Fanconi Anemia
More informationPersonalized Therapy for Acute Myeloid Leukemia. Patrick Stiff MD Loyola University Medical Center
Personalized Therapy for Acute Myeloid Leukemia Patrick Stiff MD Loyola University Medical Center 708-327-3216 Major groups of Mutations in AML Targets for AML: Is this Achievable? Chronic Myeloid Leukemia:
More informationMyelodysplastic syndrome. Jeanne Palmer, MD Mayo Clinic, Arizona
Myelodysplastic syndrome Jeanne Palmer, MD Mayo Clinic, Arizona What is Myelodysplastic syndrome? A disease where the bone marrow doesn t work appropriately What does that mean?? Red blood cells Carry
More information5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow
5/9/2018 or Stem Cell Harvest Where we are now, and What s Coming AA MDS International Foundation Indianapolis IN Luke Akard MD May 19, 2018 Infusion Transplant Conditioning Treatment 2-7 days STEM CELL
More informationFaculty of Medicine Dr. Tariq Aladily
Iron deficiency anemia The most common anemia worldwide Only 10% of ingested iron is absorbed Most dietary iron occurs in meat products Absorbed in duodenum Hepcidin By inhibiting ferroportin, hepcidin
More informationDisorder name: Severe Combined Immunodeficiency Acronym: SCID
Genetic Fact Sheets for Parents Other Disorders Screening, Technology, and Research in Genetics is a multi-state project to improve information about the financial, ethical, legal, and social issues surrounding
More informationHematology 101. Blanche P Alter, MD, MPH, FAAP Clinical Genetics Branch Division of Cancer Epidemiology and Genetics Bethesda, MD
Hematology 101 Blanche P Alter, MD, MPH, FAAP Clinical Genetics Branch Division of Cancer Epidemiology and Genetics Bethesda, MD Hematocrits Plasma White cells Red cells Normal, Hemorrhage, IDA, Leukemia,
More informationChapter 11. Hyper IgM Syndromes
Chapter 11 Hyper IgM Syndromes Patients with Hyper-IgM (HIGM) syndrome are susceptible to recurrent and severe infections and in some types of HIGM syndrome opportunistic infections and an increased risk
More informationMyelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data
Instructions for Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data (Form 2114) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the Myelodysplasia/Myeloproliferative
More informationBor-Sheng Ko. Hematology Division, Department of Internal Medicine, National Taiwan University Hospital
Bor-Sheng Ko Hematology Division, Department of Internal Medicine, National Taiwan University Hospital On behalf of Members of Aplastic Anemia Consensus Meeting Diagnosis and classification: Treatment
More informationMyelodyplastic Syndromes Paul J. Shami, M.D.
Myelodyplastic Syndromes Paul J. Shami, M.D. Professor of Hematology, University of Utah Member, Huntsman Cancer Institute Objectives Define Myelodysplastic Syndromes (MDS) Explain how MDS are diagnosed
More informationBone marrow failure. By Zahraa Nasooh Al_Saaty
Bone marrow failure By Zahraa Nasooh Al_Saaty Pancytopenia : Pancytopenia describes a reduction in the blood count of all the major cell lines-red cells,white cell and platelets. It has several causes
More informationOral squamous cell carcinoma in patients with Fanconi anemia: A case series
Goncalves et al. 42 case Case report series peer Reviewed open OPEN ACCESS Oral squamous cell carcinoma in patients with Fanconi anemia: A case series S. Goncalves, Montgomery-Cranny J., Hunter K.D., A.
More information14 2 Human Chromosomes
14-2 Human Chromosomes 1 of 25 Sex-Linked Genes Sex-Linked Genes The X chromosome and the Y chromosomes determine sex. Genes located on these chromosomes are called sex-linked genes. More than 100 sex-linked
More informationNon-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.
ERYTHROPOIESIS-STIMULATING AGENTS (ESAs) Epoetin alfa (Epogen, Procrit ) Darbepoetin alfa (Aranesp ) Methoxy polyethylene glycol (PEG) epoetin-beta (Mircera ) Non-Discrimination Statement and Multi-Language
More informationReproductive Technology, Genetic Testing, and Gene Therapy
Michael Cummings Chapter 16 Reproductive Technology, Genetic Testing, and Gene Therapy David Reisman University of South Carolina 16.1 Infertility Is a Common Problem In the US, about 13% of all couples
More informationMarrow Failure. Alan D. D Andrea, Niklas Dahl, Eva C. Guinan, and Akiko Shimamura
Marrow Failure Alan D. D Andrea, Niklas Dahl, Eva C. Guinan, and Akiko Shimamura This chapter describes the clinical presentation and molecular basis of two inherited bone marrow failure syndromes, Fanconi
More informationEpogen / Procrit. Epogen / Procrit (epoetin alfa) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.06 Section: Prescription Drugs Effective Date: April1, 2014 Subject: Epogen / Procrit Page: 1 of 7
More informationMYELODYSPLASTIC SYNDROMES: A diagnosis often missed
MYELODYSPLASTIC SYNDROMES: A diagnosis often missed D R. EMMA W YPKEMA C O N S U LTA N T H A E M AT O L O G I S T L A N C E T L A B O R AT O R I E S THE MYELODYSPLASTIC SYNDROMES DEFINITION The Myelodysplastic
More informationHEMATOLOGIC MALIGNANCIES BIOLOGY
HEMATOLOGIC MALIGNANCIES BIOLOGY Failure of terminal differentiation Failure of differentiated cells to undergo apoptosis Failure to control growth Neoplastic stem cell FAILURE OF TERMINAL DIFFERENTIATION
More informationGENETIC TESTING FOR FLT3, NPM1 AND CEBPA VARIANTS IN CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIA
CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIA Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures,
More informationHMO: Medical (provider setting); Rx (out patient) PPO/CDHP: Rx
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Epogen, Procrit (epoetin alfa, injection) Commercial HMO/PPO/CDHP
More informationCELL CYCLE REGULATION AND CANCER. Cellular Reproduction II
CELL CYCLE REGULATION AND CANCER Cellular Reproduction II THE CELL CYCLE Interphase G1- gap phase 1- cell grows and develops S- DNA synthesis phase- cell replicates each chromosome G2- gap phase 2- cell
More informationCHALLENGING CASES PRESENTATION
CHALLENGING CASES PRESENTATION Michael C. Wiemann, MD, FACP Program Co-Chair and Vice President Indy Hematology Education President, Clinical St. John Providence Physician Network Detroit, Michigan 36
More informationFriday, January 4. Bell Work:
Friday, January 4 Bell Work: Red green colorblindness is an X linked trait and is recessive. A male who is normal marries a woman who is a carrier, what is the phenotypic ratio of their offspring? 1 Genetic
More informationLeukemia Research Foundation Scientific Research Grant Recipients
Page 1 of 6 NEW INVESTIGATOR AWARDS Ioannis Aifantis, PhD The University Of Chicago, Chicago, IL $75,000 - Cooperation of Notch and pre-tcr Signaling in the Induction of T Cell Leukemia The main focus
More informationAplastic Anemia. is a bone marrow failure disease 9/19/2017. What you need to know about. The 4 major components of blood
What you need to know about Aplastic Anemia Stuart Goldberg MD Aplastic Anemia is a bone marrow failure disease The bone marrow is the factory that makes blood The 4 major components of blood Red Blood
More informationChildhood Leukemia Causes, Risk Factors, and Prevention
Childhood Leukemia Causes, Risk Factors, and Prevention Risk Factors A risk factor is anything that affects your chance of getting a disease such as cancer. Learn more about the risk factors for childhood
More informationAETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Colony Stimulating Factor (CSF)
AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Colony Stimulating Factor (CSF) Colony Stimulating Factor (CSF) Neupogen (filgrastim; G-CSF), Neulasta (peg-filgrastim; G-CSF); Neulasa
More informationLay Summaries ASH 2017
Lay Summaries ASH 2017 Purpose of Document: This document contains a collection of lay summaries of accepted ASH 2017 abstracts from the following investigators: MDS CRC Members/Affiliates, Fellows (past
More informationPatterns of Inheritance
Patterns of Inheritance Some diseases are caused by changes in genes (mutations). Remember, there are always two copies of each gene in a person, but changes in the genes can cause some genetic diseases.
More informationTargeted Chemoprevention of Progressive Marrow Failure in Patients with Fanconi Anemia using Quercetin, a Pilot study
Targeted Chemoprevention of Progressive Marrow Failure in Patients with Fanconi Anemia using Quercetin, a Pilot study Parinda Mehta, M.D. Division of Bone Marrow Transplantation and Immune Deficiency Cincinnati
More informationChapter 20: Clinical Management Checklist
Chapter 20: Clinical Management Checklist Introduction Fanconi anemia (FA) is a complex disease that can affect all systems of the body. Patients are at risk for bone marrow failure, leukemia, squamous
More informationErythropoiesis Stimulating Agents (ESA)
Erythropoiesis Stimulating Agents (ESA) Policy Number: Original Effective Date: MM.04.008 04/15/2007 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 06/01/2015 Section: Prescription
More informationMDS 101. What is bone marrow? Myelodysplastic Syndrome: Let s build a definition. Dysplastic? Syndrome? 5/22/2014. What does bone marrow do?
101 May 17, 2014 Myelodysplastic Syndrome: Let s build a definition Myelo bone marrow Gail J. Roboz, M.D. Director, Leukemia Program Associate Professor of Medicine What is bone marrow? What does bone
More informationLeukine. Leukine (sargramostim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.08 Subject: Leukine Page: 1 of 6 Last Review Date: March 13, 2014 Leukine Description Leukine (sargramostim)
More informationHAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS HLH ADULTS & Young People
HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS HLH ADULTS & Young People Histiocytosis UK Introduction Despite the misery it causes, Histiocytosis is too rare a disease to have generated substantial research in medical
More informationLeukine. Leukine (sargramostim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.08 Subject: Leukine Page: 1 of 5 Last Review Date: September 15, 2017 Leukine Description Leukine
More informationWelcome and Introductions
Information for Patients With Acute Myeloid Leukemia (AML) Welcome and Introductions Information for Patients With Acute Myeloid Leukemia (AML) Mark B. Juckett, MD Vice Chair for Clinical Affairs and Quality
More informationGenetics of Thalassemia
Genetics of Thalassemia Submitted by : Raya Samir Al- Hayaly Sura Zuhair Salih Saad Ghassan Al- Dulaimy Saad Farouq Kassir Sama Naal Salouha Zahraa Jasim Al- Aarajy Supervised by : Dr. Kawkab Adris Mahmod
More informationEarly Embryonic Development
Early Embryonic Development Maternal effect gene products set the stage by controlling the expression of the first embryonic genes. 1. Transcription factors 2. Receptors 3. Regulatory proteins Maternal
More informationThe Value of Community- Based Initiatives
The Value of Community- Based Initiatives Saving Lives Through Blood and Marrow transplantation Jeffrey Chell, MD 1 What is Bone Marrow? The blood-forming cells in the hollow portion of our bones Looks
More information2011: ALL Pre-HCT. Subsequent Transplant
2011: ALL Pre-HCT The Acute Lymphoblastic Leukemia Pre-HCT Data Form is one of the Comprehensive Report Forms. This form captures ALL-specific pre-hct data such as: the recipient s hematologic and cytogenetic
More informationINTRODUCTION TO CYTOGENETICS AND MOLECULAR TESTING IN MDS
INTRODUCTION TO CYTOGENETICS AND MOLECULAR TESTING IN MDS Saturday, September 29, 2018 Cyrus C. Hsia, HBSc, MD, FRCPC Associate Professor of Medicine, Schulich School of Medicine and Dentistry, Western
More informationEach person has a unique set of characteristics, such as eye colour, height and blood group.
1 of 51 2 of 51 What is inheritance? 3 of 51 Each person has a unique set of characteristics, such as eye colour, height and blood group. A person s characteristics are determined by a combination of the
More informationCongenital Marrow Failure Syndromes and Malignant Hematopoietic Transformation
Congenital Marrow Failure Syndromes and Malignant Hematopoietic Transformation MELVIN H. FREEDMAN Division Of Hematology/Oncology, Hospital for Sick Children, Department of Pediatrics, University of Toronto
More informationThe American Society of Hematology (ASH) represents more than 17,000 clinicians and
American Society of Hematology Statement to the House Appropriations Subcommittee on Labor, HHS, Education, and Related Agencies FY 2020 Funding for NIH and CDC The American Society of Hematology (ASH)
More informationOverview of Aplastic Anemia. Overview of Aplastic Anemia. Epidemiology of aplastic anemia. Normal hematopoiesis 10/6/2017
Overview of Aplastic Anemia Overview of Aplastic Anemia Peter Westervelt, MD, PhD Professor of Medicine Chief, BMT/Leukemia Section Washington University School of Medicine Epidemiology Normal hematopoiesis
More informationAutoimmune lymphoproliferative syndrome (ALPS)
ALPS Autoimmune lymphoproliferative syndrome (ALPS) Information for families hello@piduk.org 0800 987 8986 www.piduk.org About this leaflet This leaflet is designed to help answer the questions families
More informationChanges to the 2016 WHO Classification for the Diagnosis of MDS
Changes to the 2016 WHO Classification for the Diagnosis of MDS Welcome to Managing MDS. I am Dr. Ulrich Germing, and today, I will provide highlights from the 14th International Symposium on MDS in Valencia,
More informationChapter 28. Media Directory. Hematopoiesis. Regulation of Hematopoiesis. Erythropoietin. Drugs for Hematopoietic Disorders
Chapter 28 Drugs for Hematopoietic Disorders Slide 35 Media Directory Epoetin Alfa Animation Upper Saddle River, New Jersey 07458 All rights reserved. Hematopoiesis Figure 28.1 Hematopoiesis Process of
More informationTheme: Making Further Advancements in the Treatment of Hematologic Diseases - Frontline therapies and future prospects -
Theme: Making Further Advancements in the Treatment of Hematologic Diseases - Frontline therapies and future prospects - Professor Yutaka YATOMI, M.D., Ph.D., The Department of Clinical Laboratory Medicine,
More informationPart III of IV: Precision Medicine and Pharmacogenomics. How cancer genomics is causing a radical shift in cancer research and management
Part III of IV: Precision Medicine and Pharmacogenomics How cancer genomics is causing a radical shift in cancer research and management March 2018 Author Shealynn Buck, M.D. Chief Medical Officer Lockton
More informationDEPARTMENT OF CLINICAL HEMATOLOGY
DEPARTMENT OF CLINICAL HEMATOLOGY What is blood? Blood is the vital fluid of the body, which performs diverse functions from delivering oxygen to each and every cell of the body to fighting against infections
More informationHematopoietic Stem Cell Transplantation for Fanconi Anemia
Hematopoietic Stem Cell Transplantation for Fanconi Anemia John E. Wagner, M.D. Blood and Marrow Transplant Program University of Minnesota Cell Therapy for Pediatric Diseases NHLBI PACT Workshop 14 15
More informationCorporate Medical Policy. Policy Effective February 23, 2018
Corporate Medical Policy Genetic Testing for FLT3, NPM1 and CEBPA Mutations in Acute File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_flt3_npm1_and_cebpa_mutations_in_acute_myeloid_leukemia
More informationAbout Myelodysplastic Syndromes
About Myelodysplastic Syndromes Overview and Types If you have been diagnosed with a myelodysplastic syndrome or are worried about it, you likely have a lot of questions. Learning some basics is a good
More informationAsingle inherited mutant gene may be enough to
396 Cancer Inheritance STEVEN A. FRANK Asingle inherited mutant gene may be enough to cause a very high cancer risk. Single-mutation cases have provided much insight into the genetic basis of carcinogenesis,
More informationRydapt. Summary of the Risk Management Plan (RMP) for Rydapt (midostaurin)
Regulatory Affairs Rydapt 25 mg soft capsules Summary of the Risk Management Plan (RMP) for Rydapt (midostaurin) Document version: 01 Document status: Document Date: Final 02-June-2017 1 of 6 Summary of
More informationAndrew Schorr: Dr. Young, for patients receiving initial treatment could you discuss the findings comparing horse ATG and rabbit ATG?
What s New in Aplastic Anemia Treatment American Society of Hematology Meeting December 2011 Dr. Neal S. Young Please remember the opinions expressed on Patient Power are not necessarily the views of our
More informationHths 2231 Laboratory 3 Genetics
Watch Movie: Cystic Fibrosis Answer the movie questions on the worksheet. Complete activities 1-5 Activity #1: Under Lab 3 Click on activity 1 Click on Tour of the Basics Do all 6 What is exercises Activity
More information